Company expects to recruit approximately 10 sites across the United States
Presentation to Highlight the Promise of Novel Gene Therapies to Transform Cancer and Diabetes Treatments
Thomas Gallagher, Senior VP of Intellectual Property and Licensing, to provide insight into IP best practices to early-stage companies
Inventor of the Company’s licensed diabetes gene therapy technology to provide leadership, strategy for diabetes program
An experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Co’s Keytruda – both leading their respective drug classes in the treatment of non-small cell lung cancer (NSCLC).
Genprex announced that quaratusugene ozeplasmid (Reqorsa) will be studied in two new trials, in which non-small cell lung cancer patients with specific molecular markers will receive its investigational drug combined with osimertinib (AstraZeneca's Tagrisso) or pembrolizumab (Merck's Keytruda).
Designed and Secured by Barsec